Recurrent Mucocutaneous Herpes Simplex — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for recurrent mucocutaneous herpes simplex. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
3
Active US patents
79/100
Avg vulnerability
—
Annual revenue covered

Originators in Recurrent Mucocutaneous Herpes Simplex

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ligand Pharms 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating recurrent mucocutaneous herpes simplex. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zovirax
ACYCLOVIR
 Ligand Pharms 3 79 — 2027-03-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8791127 Zovirax method of use 85 2027-03-23
8747896 Zovirax method of use 80 2027-06-03
8592434 Zovirax method of use 73 2030-06-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8592434 Zovirax method of use 73 2030-06-16
8747896 Zovirax method of use 80 2027-06-03
8791127 Zovirax method of use 85 2027-03-23

Related